Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis
Yıl: 2023 Cilt: 48 Sayı: 3 Sayfa Aralığı: 549 - 560 Metin Dili: İngilizce DOI: 10.55262/fabadeczacilik.1356769 İndeks Tarihi: 04-12-2023
Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis
Öz: Cancer stem cells play an important role in resistance to therapy, invasion, metastasis, and recurrence. CD44 is one of the well-known surface markers for hepatocellular carcinoma and its expression level is related to poor survival and a high recurrence rate. The effect of phenethyl isothiocyanate (PEITC) on SNU449 hepatocellular carcinoma cell line cancer stem cells is not known. The goal of the present study was to investigate whether PEITC regulates the cancer stem cell phenotype of SNU449 cells. Here, cell viability, colony formation, and wound healing assays were performed to determine proliferative and migratory characteristics. Additionally, Caspase 3, CD44, Akt/mTOR, and p38/STAT3 protein expression levels were measured by western blotting. We found that compared to control confluence, gap fill, and migration rate were increased while half gap time was decreased in PEITC-treated cells. Compared to control-treated cells CD44 (3.2 fold) and p-STAT3 (2.44 fold) protein expressions were upregulated in PEITC-treated cells. Results of this study suggest that STAT3-mediated upregulation of CD44 leads to the gain of cancer stem cell phenotype of PEITC-treated SNU449 cells.
Anahtar Kelime: Fenetil izotiyosiyanat SNU449 hepatoselüler karsinom hücrelerinin kanser kök hücre fenotipini STAT3-CD44 yolu ile düzenler
Öz: Kanser kök hücreleri tedavi direnci, invazyon, metastaz ve nükste önemli rol oynar. Hepatoselüler karsinom için bilinen yüzey belirteçlerinden biri olan CD44’ ün ekspresyon seviyesi hayatta kalma süresinin kısalması ve yüksek nüks oranı ile ilişkilidir. Fenetil izotiyosiyanatın (PEITC) SNU449 hepatoselüler karsinom hücre hattı kanser kök hücreleri üzerindeki etkisi bilinmemektedir. Bu çalışmanın amacı, PEITC’nin SNU449 hücrelerinin kanser kök hücre fenotipini nasıl düzenlediğini araştırmaktır. Çoğalma ve göç özelliklerini belirlemek için hücre canlılık, koloni oluşum ve yara iyileşme testleri gerçekleştirilmiştir. Kaspaz 3, CD44, Akt/mTOR ve p38/STAT3 protein ekspresyonları Western blotlama ile ölçülmüştür. PEITC uygulanan hücrelerde hücre yoğunluğu, boşluk doldurma ve göç hızı artarken, yarı boşluk zamanının azaldığı bulunmuştur. PEITC uygulanan hücrelerde, CD44 protein seviyesi 3.2 kat ve p-STAT3 protein seviyesi 2.4 kat daha yüksek bulunmuştur. Bu çalışmanın sonuçları, PEITC uygulanan SNU449 hücrelerinin kanser kök hücre fenotipini kazanmasına STAT3-aracılı olarak artan CD44 seviyelerinin neden olduğunu göstermektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Askan, G., Sahin, I. H., Chou, J. F., Yavas, A., Capa- nu, M., Iacobuzio-Donahue, C. A., Basturk, O., O’Reilly, E. M. (2021). Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal ad- enocarcinoma. BMC Cancer, 21, 385. https://doi. org/10.1186/s12885-021-08123-w
- Ayob, A. Z., & Ramasamy, T. S. (2018). Cancer stem cells as key drivers of tumour progression. Jour- nal of Biomedical Science, 25, 20. https://doi. org/10.1186/s12929-018-0426-4
- Borlongan, M. C., & Wang, H. (2023). Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics. Frontiers in Cell and Devel- opmental Biology, 11(May), 1–33. https://doi. org/10.3389/fcell.2023.1125174
- Chen, J., Shao, R., Li, F., Monteiro, M., Liu, J. P., Xu, Z. P., & Gu, W. (2015). PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clinical and Experimental Pharmacology and Physiology, 42(12), 1317–1326. https://doi.org/10.1111/1440-1681.12493
- Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2019). Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer che- moresistance through reversing epithelial-mes- enchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 19(1), 618. https://doi.org/10.1186/s12885-019-5824-9
- Karami fath, M., Ebrahimi, M., Nourbakhsh, E., Hazara, A. Z., Mirzaei, A., Shafieyari, S., Sale- hi, A., Hoseinzadeh, M., Payandeh, Z., Barati, G. (2022). PI3K/Akt/mTOR signaling pathway in cancer stem cells. Pathology - Research and Practice, 237, 154010. https://doi.org/10.1016/j. prp.2022.154010
- Kim, J., Jiang, J., Badawi, M., & Schmittgen, T. D. (2017). miR-221 regulates CD44 in hepatocel- lular carcinoma through the PI3K-AKT-mTOR pathway. Biochemical and Biophysical Research Communications, 487(3), 709–715. https://doi. org/10.1016/j.bbrc.2017.04.121
- Koyama, S., Tsuchiya, H., Amisaki, M., Sakaguchi, H., Honjo, S., Fujiwara, Y., & Shiota, G. (2020). NEAT1 is Required for the Expression of the Liv- er Cancer Stem Cell Marker CD44. International Journal of Molecular Sciences, 21(6), 1927. https:// doi.org/10.3390/ijms21061927
- Lv, D., Chen, L., Du, L., Zhou, L., & Tang, H. (2021). Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellu- lar Carcinoma. Frontiers in Cell and Developmen- tal Biology, 9(July), 1–13. https://doi.org/10.3389/ fcell.2021.691410
- Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019). Immune Regulation and Cancer Progression. Cancers, 11(12), 2002. https://doi.org/10.3390/ cancers11122002
- Sayiner, M., Golabi, P., & Younossi, Z. M. (2019). Disease Burden of Hepatocellular Carcinoma : A Global Perspective. Digestive Diseases and Sci- ences, 64(4), 910–917. https://doi.org/10.1007/ s10620-019-05537-2
- Shin, J. M., Lim, E., Cho, Y. S., & Nho, C. W. (2021). Cancer-preventive effect of phenethyl isothiocy- anate through tumor microenvironment regu- lation in a colorectal cancer stem cell xenograft model. Phytomedicine, 84, 153493. https://doi. org/10.1016/j.phymed.2021.153493
- Song, L., Zhang, H., Hu, M., Liu, C., Zhao, Y., Zhang, S., & Liu, D. (2021). Sinomenine inhibits hypoxia induced breast cancer side population cells metas- tasis by PI3K / Akt / mTOR pathway. Bioorganic & Medicinal Chemistry, 31, 115986. https://doi. org/10.1016/j.bmc.2020.115986
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soer- jomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Can- cers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/ caac.21660
- Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., Simeone, D. M., Zou, W., Welling, T. H. (2014). Tumor-associated macrophages pro- duce interleukin 6 and signal via STAT3 to pro- mote expansion of human hepatocellular carci- noma stem cells. Gastroenterology, 147(6), 1393– 1404. https://doi.org/10.1053/j.gastro.2014.08.039
- Xie, P., Yan, J., Wu, M., Li, H., Chen, Z., Yu, M., Zhang, B., Chen, L., Jin, L., Zhou, B., Li, X., Xiao, Y., Xu, Y., Long, J., Zhang, J., Guo, L. (2022). CD44 po- tentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT/ERK signal- ing CXCR4 axis. Annals of Translational Medicine, 10(12), 1–16. https://doi.org/10.21037/atm-22- 2482
- Xie, X. P., Laks, D. R., Sun, D., Ganbold, M., Wang, Z., Pedraza, A. M., Bale, T., Tabar, V., Brennan, C., Zhou, X., Parada, L. F. (2022). Quiescent hu- man glioblastoma cancer stem cells drive tumor initiation , expansion , and recurrence follow- ing chemotherapy. Developmental Cell, 57(Jan- uary 10), 32–46. https://doi.org/10.1016/j.dev- cel.2021.12.007
- Yang, B., Li, M., Tang, W., Liu, W., Zhang, S., Chen, L., & Xia, J. (2018). Dynamic network biomarker in- dicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nature Communica- tions, 9, 678. https://doi.org/10.1038/s41467-018- 03024-2
- Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., Cui, H. (2020). Targeting cancer stem cell pathways for cancer therapy. In Signal Transduction and Target- ed Therapy, 5, 8. https://doi.org/10.1038/s41392- 020-0110-5
- Yao, H., Sun, L., Li, J., Zhou, X., Li, R., Shao, R., Zhang, Y. Li, L. (2020). A Novel Therapeutic siR- NA Nanoparticle Designed A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Target- ing CD44 and Gli1 of Gastric Cancer Stem Cells. International Journal of Nanomedicine, 15, 7013– 7034. https://doi.org/10.2147/IJN.S260163
- Yun, J. H., Kim, K. A., Yoo, G., Kim, S. Y., Shin, J. M., Kim, J. H., Jung, S. H., Kim, J., Nho, C. W. (2017). Phenethyl isothiocyanate suppresses can- cer stem cell properties in vitro and in a xenograft model. Phytomedicine, 30, 42–49. https://doi. org/10.1016/j.phymed.2017.01.015
- Zhang, H.-L., Wang, P., Lu, M.-Z., Zhang, S.-D., & Zheng, L. (2019). c - Myc maintains the self - re- newal and chemoresistance properties of colon cancer stem cells. Oncology Letters, 17, 4487–4493. https://doi.org/10.3892/ol.2019.10081
| APA | Satılmış B (2023). Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. , 549 - 560. 10.55262/fabadeczacilik.1356769 |
| Chicago | Satılmış Basri Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. (2023): 549 - 560. 10.55262/fabadeczacilik.1356769 |
| MLA | Satılmış Basri Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. , 2023, ss.549 - 560. 10.55262/fabadeczacilik.1356769 |
| AMA | Satılmış B Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. . 2023; 549 - 560. 10.55262/fabadeczacilik.1356769 |
| Vancouver | Satılmış B Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. . 2023; 549 - 560. 10.55262/fabadeczacilik.1356769 |
| IEEE | Satılmış B "Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis." , ss.549 - 560, 2023. 10.55262/fabadeczacilik.1356769 |
| ISNAD | Satılmış, Basri. "Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis". (2023), 549-560. https://doi.org/10.55262/fabadeczacilik.1356769 |
| APA | Satılmış B (2023). Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. FABAD Journal of Pharmaceutical Sciences, 48(3), 549 - 560. 10.55262/fabadeczacilik.1356769 |
| Chicago | Satılmış Basri Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. FABAD Journal of Pharmaceutical Sciences 48, no.3 (2023): 549 - 560. 10.55262/fabadeczacilik.1356769 |
| MLA | Satılmış Basri Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. FABAD Journal of Pharmaceutical Sciences, vol.48, no.3, 2023, ss.549 - 560. 10.55262/fabadeczacilik.1356769 |
| AMA | Satılmış B Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. FABAD Journal of Pharmaceutical Sciences. 2023; 48(3): 549 - 560. 10.55262/fabadeczacilik.1356769 |
| Vancouver | Satılmış B Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis. FABAD Journal of Pharmaceutical Sciences. 2023; 48(3): 549 - 560. 10.55262/fabadeczacilik.1356769 |
| IEEE | Satılmış B "Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis." FABAD Journal of Pharmaceutical Sciences, 48, ss.549 - 560, 2023. 10.55262/fabadeczacilik.1356769 |
| ISNAD | Satılmış, Basri. "Phenethyl isothiocyanate Regulates the Cancer Stem Cell Phenotype of SNU449 Hepatocellular Carcinoma Cells via STAT3-CD44 Axis". FABAD Journal of Pharmaceutical Sciences 48/3 (2023), 549-560. https://doi.org/10.55262/fabadeczacilik.1356769 |
